{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:37:04Z","timestamp":1793165824787,"version":"4.5.0"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T00:00:00Z","timestamp":1331769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Evaluation Clinical Practice"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Rationale, aims and objectives\u2002<\/jats:bold> There is little evidence regarding the benefit of stress ulcer prophylaxis (SUP) outside a critical care setting. Overprescription of SUP is not devoid of risks. This prospective study aimed to evaluate the use of proton pump inhibitors (PPIs) for SUP in a general surgery department.<\/jats:p><jats:p><jats:bold>Method\u2002<\/jats:bold> Data collection was performed prospectively during an 8\u2010week period on patients hospitalized in a general surgery department (58 beds) by pharmacists. Patients with a PPI prescription for the treatment of ulcers, gastro\u2010oesophageal reflux disease, oesophagitis or epigastric pain were excluded. Patients admitted twice during the study period were not reincluded. The American Society of Health\u2010System Pharmacists guidelines on SUP were used to assess the appropriateness of <jats:italic>de novo<\/jats:italic> PPI prescriptions.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Among 255 patients in the study, 138 (54%) received a prophylaxis with PPI, of which 86 (62%) were <jats:italic>de novo<\/jats:italic> PPI prescriptions. A total of 129 patients (94%) received esomeprazole (according to the hospital drug policy). The most frequent dosage was at 40\u2003mg once daily. Use of PPI for SUP was evaluated in 67 patients. A total of 53 patients (79%) had no risk factors for SUP. Twelve and two patients had one or two risk factors, respectively. At discharge, PPI prophylaxis was continued in 33% of patients with a <jats:italic>de novo<\/jats:italic> PPI prescription.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> This study highlights the overuse of PPIs in non\u2010intensive care unit patients and the inappropriate continuation of PPI prescriptions at discharge. Treatment recommendations for SUP are needed to restrict PPI use for justified indications.<\/jats:p>","DOI":"10.1111\/j.1365-2753.2012.01838.x","type":"journal-article","created":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T12:50:41Z","timestamp":1331815841000},"page":"374-378","source":"Crossref","is-referenced-by-count":23,"title":["Stress ulcer prophylaxis in non\u2010critically ill patients: a prospective evaluation of current practice in a general surgery department"],"prefix":"10.1111","volume":"19","author":[{"given":"Coraline","family":"Bez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Perrottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Zingg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En\u2010Ling","family":"Leung Ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Demartines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Pannatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-007-9531-2"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2006.00742.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00839.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01600.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AACN.0000269254.39967.8e"},{"key":"e_1_2_5_7_2","first-page":"347","article-title":"ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998","volume":"56","author":"ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis","year":"1999","journal-title":"American Journal of Health-System Pharmacy"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.10"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.115"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02216.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.16.1955"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.23.2989"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199912000-00034"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402103300601"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91843-0"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i8.982"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015395103160"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00499.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000157751.92249.32"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02454.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629090-00002"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.082001"}],"container-title":["Journal of Evaluation in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2753.2012.01838.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2753.2012.01838.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T03:48:37Z","timestamp":1697341717000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2753.2012.01838.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,15]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/j.1365-2753.2012.01838.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2753.2012.01838.x","archive":["Portico"],"relation":{},"ISSN":["1356-1294","1365-2753"],"issn-type":[{"value":"1356-1294","type":"print"},{"value":"1365-2753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,15]]}}}